Market Cap 14.68B
Revenue (ttm) 2.36B
Net Income (ttm) 341.30M
EPS (ttm) N/A
PE Ratio 35.29
Forward PE 27.80
Profit Margin 14.49%
Debt to Equity Ratio 0.00
Volume 359,600
Avg Vol 1,035,112
Day's Range N/A - N/A
Shares Out 99.71M
Stochastic %K 41%
Beta 0.27
Analysts Strong Sell
Price Target $179.04

Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat cong...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 858 617 7600
Address:
12780 El Camino Real, San Diego, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 2:11 PM
$NBIX RSI: 41.41, MACD: -0.0228 Vol: 4.62, MA20: 150.58, MA50: 146.29 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 23 at 1:41 PM
$NBIX (-0.4% pre) Neurocrine KINECT study fails to meet primary endpoints for cerebral palsy https://ooc.bz/l/88254
0 · Reply
GoIrish1776
GoIrish1776 Dec. 23 at 4:37 AM
$NBIX Austedo failed in CP long ago. No one is surprised. Only surprise is why management bothered to keep going.
0 · Reply
AudraAllen1103
AudraAllen1103 Dec. 23 at 1:18 AM
$NBIX Phase 3 KINECT-DCP study of Valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP) did not meet primary or key secondary endpoints.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 22 at 10:21 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:08 PM
Actionable Trade Alert for $NBIX: Market Context: $NBIX is currently trading at $141.84, showing potential for a rebound given the oversold RSI of 28.6. The stock is below its 30-day moving average (MA30) of 148.52 and 50-day moving average (MA50) of 145.47, indicating a bearish trend. However, the recent 60-day low of 133.61 suggests a support level, creating a favorable risk-reward setup. Directional Bias: The RSI indicates oversold conditions, which often precedes a price correction. The proximity to the 60-day low further supports a bullish reversal. Trade Plan: - Suggested Entry: $142.50 - Stop Loss: $138.00 (below recent support) - Take Profit Targets: 1. $150.00 (5.3% ROI) 2. $155.00 (8.8% ROI) 3. $166.00 (17.0% ROI) This plan leverages the potential for a rebound while managing risk effectively. Monitor market conditions closely for any changes. https://privateprofiteers.com
0 · Reply
GoIrish1776
GoIrish1776 Dec. 17 at 10:11 PM
$NBIX I mean, really? This stuff gets SO old with this stock.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:05 PM
HC Wainwright & Co. updates rating for Neurocrine Biosciences ( $NBIX ) to Buy, target set at 168 → 198.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:55 AM
Actionable Trade Alert for $NBIX: Market Context: $NBIX is currently trading at $148.74, exhibiting bullish momentum. The RSI at 64.45 indicates that the stock is approaching overbought territory but still has room for upward movement. The 30-day moving average (MA30) at $148.57 supports a bullish outlook, as the price is above this level. The stock is also well above the 50-day MA at $145.33, indicating strong short-term strength. Directional Bias: Given the current price relative to the MAs and the recent high of $160.18, there is potential for further gains. The price is within the range of the 60-day high and low, suggesting a bullish bias. Trade Plan: - Suggested Entry: $149.00 - Stop Loss: $144.00 (approx. 3.5% risk) - Take Profit Targets: 1. $155.00 (Target 1: 4.03% ROI) 2. $160.00 (Target 2: 7.54% ROI) 3. $174.00 (Target 3: 16.93% ROI) This plan offers a potential ROI of over 17% on the third target while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
GoIrish1776
GoIrish1776 Dec. 16 at 11:14 PM
$NBIX I was half joking about the R&D day in my earlier post but I have to say the strategic decision to go after obesity is suspect. The market is very crowded, innovative, and prices continue to be driven down. I’m not sold.
1 · Reply
Latest News on NBIX
Neurocrine Biosciences to Host R&D Day on December 16

Dec 9, 2025, 4:01 PM EST - 15 days ago

Neurocrine Biosciences to Host R&D Day on December 16


OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 2:11 PM
$NBIX RSI: 41.41, MACD: -0.0228 Vol: 4.62, MA20: 150.58, MA50: 146.29 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 23 at 1:41 PM
$NBIX (-0.4% pre) Neurocrine KINECT study fails to meet primary endpoints for cerebral palsy https://ooc.bz/l/88254
0 · Reply
GoIrish1776
GoIrish1776 Dec. 23 at 4:37 AM
$NBIX Austedo failed in CP long ago. No one is surprised. Only surprise is why management bothered to keep going.
0 · Reply
AudraAllen1103
AudraAllen1103 Dec. 23 at 1:18 AM
$NBIX Phase 3 KINECT-DCP study of Valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP) did not meet primary or key secondary endpoints.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 22 at 10:21 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:08 PM
Actionable Trade Alert for $NBIX: Market Context: $NBIX is currently trading at $141.84, showing potential for a rebound given the oversold RSI of 28.6. The stock is below its 30-day moving average (MA30) of 148.52 and 50-day moving average (MA50) of 145.47, indicating a bearish trend. However, the recent 60-day low of 133.61 suggests a support level, creating a favorable risk-reward setup. Directional Bias: The RSI indicates oversold conditions, which often precedes a price correction. The proximity to the 60-day low further supports a bullish reversal. Trade Plan: - Suggested Entry: $142.50 - Stop Loss: $138.00 (below recent support) - Take Profit Targets: 1. $150.00 (5.3% ROI) 2. $155.00 (8.8% ROI) 3. $166.00 (17.0% ROI) This plan leverages the potential for a rebound while managing risk effectively. Monitor market conditions closely for any changes. https://privateprofiteers.com
0 · Reply
GoIrish1776
GoIrish1776 Dec. 17 at 10:11 PM
$NBIX I mean, really? This stuff gets SO old with this stock.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:05 PM
HC Wainwright & Co. updates rating for Neurocrine Biosciences ( $NBIX ) to Buy, target set at 168 → 198.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:55 AM
Actionable Trade Alert for $NBIX: Market Context: $NBIX is currently trading at $148.74, exhibiting bullish momentum. The RSI at 64.45 indicates that the stock is approaching overbought territory but still has room for upward movement. The 30-day moving average (MA30) at $148.57 supports a bullish outlook, as the price is above this level. The stock is also well above the 50-day MA at $145.33, indicating strong short-term strength. Directional Bias: Given the current price relative to the MAs and the recent high of $160.18, there is potential for further gains. The price is within the range of the 60-day high and low, suggesting a bullish bias. Trade Plan: - Suggested Entry: $149.00 - Stop Loss: $144.00 (approx. 3.5% risk) - Take Profit Targets: 1. $155.00 (Target 1: 4.03% ROI) 2. $160.00 (Target 2: 7.54% ROI) 3. $174.00 (Target 3: 16.93% ROI) This plan offers a potential ROI of over 17% on the third target while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
GoIrish1776
GoIrish1776 Dec. 16 at 11:14 PM
$NBIX I was half joking about the R&D day in my earlier post but I have to say the strategic decision to go after obesity is suspect. The market is very crowded, innovative, and prices continue to be driven down. I’m not sold.
1 · Reply
GoIrish1776
GoIrish1776 Dec. 16 at 9:03 PM
$NBIX I guess the R&D day was a hit.
0 · Reply
stoxx0007
stoxx0007 Dec. 15 at 8:58 PM
$NBIX = nice little green 💚 spot here. 😁👏
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:28 AM
Actionable Trade Alert for $NBIX: Market Context: $NBIX closed at $152.79, showing strong momentum with an RSI of 74.42, indicating overbought conditions. However, the price is above both the 30-day MA (148.34) and 50-day MA (145.07), suggesting bullish sentiment. Directional Bias: The price is approaching the 60-day high of 160.18, which may act as a resistance level. Given the current RSI and proximity to the high, a pullback could occur, but the overall trend remains bullish. Trade Plan: - Suggested Entry: $152.79 - Stop Loss: $148.00 (below the 30-day MA) - Take Profit Targets: 1. $158.00 (3.5% gain) 2. $162.00 (6.0% gain) 3. $179.00 (17.2% gain) With a clear bullish trend and potential for significant upside, consider this trade while managing risk with the stop loss. Monitor for any signs of reversal as you approach the targets. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 2:18 PM
Mizuho has updated their rating for Neurocrine Biosciences ( $NBIX ) to Neutral with a price target of 175.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:22 PM
Actionable Trade Alert for $NBIX: Market Context: $NBIX closed at $154.65, showing strong momentum with an RSI of 83.44, indicating overbought conditions. The stock is trading above its 30-day (MA30) and 50-day (MA50) moving averages, which are at $147.85 and $144.74, respectively. The recent 60-day high of $160.18 suggests potential resistance ahead. Directional Bias: Given the high RSI and proximity to the 60D high, there is a bullish sentiment, but caution is warranted due to overbought conditions. Trade Plan: - Suggested Entry: $155.00 - Stop Loss: $149.00 (approximately 4% below entry) - Take Profit Targets: - TP1: $160.00 (3.23% gain) - TP2: $165.00 (6.45% gain) - TP3: $181.00 (16.99% gain) With a potential ROI of 17% or more on TP3, this trade offers a favorable risk-reward ratio. Monitor price action closely as it approaches targets. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 1:30 PM
Stifel has updated their rating for Neurocrine Biosciences ( $NBIX ) to Buy with a price target of 188.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:25 AM
Actionable Trade Alert for $NBIX: Market Context: $NBIX is currently trading at $155.02, showing strong momentum with an RSI of 85.13, indicating overbought conditions. The price is above both the 30-day moving average (MA30) of $147.02 and the 50-day moving average (MA50) of $144.09, suggesting bullish sentiment. However, the high of $160.18 from the last 60 days is a critical resistance level. Directional Bias: Given the high RSI and proximity to the 60D high, we anticipate a potential pullback or consolidation before further upward movement. Trade Plan: - Suggested Entry: $155.02 - Stop Loss: $150.68 (approximately 3% below entry) - Take Profit Targets: 1. $160.00 (3.2% gain) 2. $165.00 (6.4% gain) 3. $182.00 (17.4% gain) This trade plan allows for a favorable risk-reward ratio while targeting significant upside potential. Monitor the price action closely near resistance levels. https://privateprofiteers.com
0 · Reply
RunnerSignals
RunnerSignals Dec. 9 at 9:34 PM
Stock Upgrades Today ​$OCUL $KMDA $LEGN $BIOA $NBIX Biotech stars breaking out https://stocksrunner.com/news/2025-12-09-stock-upgrades-today-show-top-picks
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:13 PM
Actionable Trade Alert for $NBIX: Market Context: $NBIX is currently trading at $157.56, with a strong RSI of 73.52 indicating overbought conditions. However, it remains above its 30-day moving average (MA30) of 146.9 and 50-day moving average (MA50) of 143.84, suggesting bullish momentum. Directional Bias: The price is near the 60-day high of $160.18, indicating potential resistance. The RSI suggests caution, but the overall trend remains upward. Trade Plan: - Suggested Entry: $157.56 - Stop Loss: $153.08 (approximately 3% below entry) - Take Profit Targets: 1. Target 1: $160.00 (1.55% gain) 2. Target 2: $165.00 (4.71% gain) 3. Target 3: $184.00 (16.84% gain) Target 3 provides a potential ROI of 17% or more, aligning with our strategy for significant gains. Monitor the price action closely as it approaches the targets. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 2:39 PM
RBC Capital has updated their rating for Neurocrine Biosciences ( $NBIX ) to Outperform with a price target of 180.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 8 at 1:54 PM
Our earlier post compared $NBIX Crenessity product revenue post FDA approval/launch to peers acquired in that $10B range like Verona & Immunogen suggesting, but not confirming, NBIX's Crenessity might be worthj a similar number in a M&A exit. Here we show valuation & revenue projection data for the 10 commercial-stage non-oncology focused peers with market caps ranging from $6 to $15B. NBIX's Ingrezza is a powerhouse by itself on track to doing $2.5B in FY25. This is not investment advice but we really like NBIX. $RYTM has a great drug with multiple catalysts nearing including a PDUFA & a P3 read. Still RYTM trades at a very high multiple of analyst revenue estimates compared to these peers. $CORT Relacorilant has an upcoming PDUFA in Cushing's followed by ovarian cancer. We considered CORT non-oncology but that will change if approved. $BMRN is a great company but to us appears a textbook example of the risks of staying independent. BMRN is down ~50% from Xmas 2015. $IONS was the same ?
2 · Reply